Illumina focuses on molecular diagnostics

San Diego-based Illumina has created two new business units. The Life Sciences Business Unit will include all products and services related to the company's sequencing and genotyping business. And with the new Diagnostics Business Unit, Illumina will attempt to tap into the hot molecular diagnostics market.

"This new organizational structure provides the foundation to continue scaling our global operations...A specific result will be the acceleration of the integration of our sequencing and genotyping technologies. Additionally, it will enable us to put more focus on developing our diagnostics business," said Jay Flatley, Illumina's President and CEO. The company also announced a number of management changes, and said that it's now in search of a product development VP and an operations VP.

- see Illumina's release for more

Suggested Articles

Two weeks after receiving a second dose of Moderna's COVID-19 jab, patients had "robust" levels of neutralizing antibodies against the…

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.